Clinical observation of evolocumab combined with atorvastatin in the treatment of borderline coronary artery disease
- VernacularTitle:依洛尤单抗联合阿托伐他汀治疗冠心病临界病变的临床观察
- Author:
Ruiya SU
1
;
Lichuang WANG
2
;
Ou ZHANG
1
;
Xianfeng ZENG
1
;
Xian WEN
1
Author Information
1. Coronary Care Unit，the First Affiliated Hospital of Nanyang Medical College，Henan Nanyang 473000，China
2. Dept. of Clinical Medicine，Nanyang Medical College，Henan Nanyang 473000，China
- Publication Type:Journal Article
- Keywords:
evolocumab;
atorvastatin;
borderline lesion;
coronary heart disease;
coronary artery plaque;
luminal stenosis
- From:
China Pharmacy
2026;37(10):1318-1322
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To observe the clinical efficacy of evolocumab combined with atorvastatin in the treatment of patients with borderline coronary heart disease （CHD）. METHODS In this retrospective cohort study， 342 hospitalized patients diagnosed with borderline CHD were enrolled in the First Affiliated Hospital of Nanyang Medical College from August 2021 to June 2024， and divided into control group （treated with atorvastatin， 190 cases） and trial group （treated with evolocumab combined with atorvastatin， 152 cases） according to therapeutic regimen. Blood lipid indexes， high-sensitivity C-reactive protein （hs-CRP） and intravascular ultrasound of the coronary artery at baseline and after 1 year of treatment， and incidence of cardiovascular adverse events were compared after propensity score matching. RESULTS A total of 295 patients （158 in control group and 137 in trial group） were finally included in the analysis. One year after the treatment， compared with control group， total cholesterol， triglycerides， low-density lipoprotein cholesterol and hs-CRP levels were decreased significantly in trial group （ P ＜0.05）， whereas high-density lipoprotein cholesterol level was increased significantly （ P ＜0.05）. The lumen diameter， lumen area， and the minimum lumen area were significantly increased （ P ＜0.05）， while plaque area and plaque burden were significantly decreased （ P ＜0.05）. Overall incidence of adverse events in trial group was significantly lower than that in control group （ P ＜0.05）. CONCLUSIONS Evolocumab combined with atorvastatin can significantly improve coronary luminal narrowing and reduce plaque burden， as well as reduce the incidence of cardiovascular adverse events in patients with borderline CHD.
